Comparing two chemotherapy plans for colorectal cancer with MRD
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study compares two different chemotherapy combinations given after surgery to prevent cancer from coming back in people with colorectal cancer who have minimal residual disease (MRD), meaning there are still tiny traces of cancer DNA in the blood. A more intense regimen may work better for this group, and the trial checks if it is safe and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You were recently diagnosed with stage II or III colon or rectal cancer (adenocarcinoma).
- You had surgery to remove the cancer, and there were no cancer cells left behind (called R0 resection).
- After surgery, a blood test showed that there were still traces of cancer DNA in your blood (called MRD positive).
- You have not had any chemotherapy or radiation before your surgery.
- You have no other active cancers and no serious heart or blood-clotting problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares the effects of a combination of two chemotherapy drugs (CAPEOX) versus close monitoring (active surveillance) in early-stage colorectal cancer patients who have a positive MRD blood test after surgery. The goal is to see if giving chemotherapy can reduce the risk of cancer returning compared to just watching.
This trial is for people with early-stage colon cancer (stage II high-risk or stage III low-risk) that is not MSI-H. It uses a blood test (MRD) to see if you can safely delay or skip extra chemotherapy after surgery, based on whether the test finds any leftover cancer cells.
This Phase 2 trial tests whether a newer combination chemotherapy plus an immunotherapy medicine (cadonilimab/AK104) works better than standard chemotherapy before surgery for locally advanced colorectal cancer. The goal is to shrink the tumor and improve how well treatment works after surgery.
This study looks at how well targeted therapies work for people with colorectal cancer who have minimal residual disease (MRD, tiny amounts of cancer left after treatment) detected by a blood test. It is for people who have a specific genetic change (biomarker) in their tumor and have not been treated with the targeted therapy for that biomarker before.
This trial compares two different chemotherapy combinations given before surgery for locally advanced colon cancer. One option adds an immunotherapy drug to the chemo. The goal is to see which approach works better at shrinking the tumor and improving outcomes.
This trial compares two standard chemotherapy combinations for people whose colorectal cancer has spread and cannot be removed with surgery. Depending on certain genetic markers, participants also receive either bevacizumab or cetuximab to help the treatment work better.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.